Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with newly diagnosed multiple myeloma (MM). CR is one of the best predictors of long-term survival. These three studies were selected for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 30 - June 3, 2008. Highlights included:

-- VELCADE, cyclophosphamide, and dexamethasone (CyBorD) demonstrated a

CR rate of 46 percent prior to transplant and 72 percent

post-transplant

-- VELCADE, DOXIL and dexamethasone (PAD or VcDD) prior to transplant

showed a CR rate of 21 percent which increased to 59 percent

post-transplant

-- VELCADE, lenalidomide and dexamethasone (VRD) showed a CR rate of 35

percent at maximum planned dose and a 100 percent overall response

rate.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The goal of first-line therapy is to rapidly achieve the deepest and most durable response possible," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "VELCADE based combinations produce among the highest CR rates that are similar to those achieved by high dose therapy and transplantation. These very strong results underscore the critical role of VELCADE in patients with newly diagnosed multiple myeloma."

Efficacy of Induction with CyBorD in Newly Diagnosed Multiple Myeloma (Abstract #8517)

This study of CyBorD was designed to determine response in patients with newly diagnosed multiple myeloma. The results showed the status of 28 evaluable patients, who received cyclophosphamide at 300 mg/m2 on days 1, 8, 15, 22, VELCADE at 1
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Sutro Biopharma today announced that it has been named ... 15 biotechnology companies, designating it as one of the ... "Sutro has earned some careful attention from ... partners for what promises to be a next-gen approach ... Carroll , editor of FierceBiotech .  "This is ...
(Date:9/22/2014)... 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... present a corporate overview and update at the NewsMakers ... 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific ... New York City . A live ... the investor relations section of Arena,s website at ...
(Date:9/22/2014)... YORK , Sept. 22, 2014 ... exclusive, global license agreement with Plasma Technologies LLC ... proprietary plasma fractionation process. Concurrently, the Company announced ... to strategically refocus and rebrand the company as ... a national listing for its common shares. ...
Breaking Medicine Technology:FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... , SEATTLE , Feb. 11 ... systems, today announced record 2009 sales results. The successful launch ... growth in excess of 75% and the company,s first cash ... consumed the company,s manufacturing capacity for 2009 and well into ...
... DENVER , Feb. 11 Corgenix Medical Corporation ... test kits, today filed its 2nd quarter Form 10-Q and reported ... declined during the quarter but slightly increased for the six months ... by the report are as follows: , Revenues for the ...
Cached Medicine Technology:Amnis Announces Record 2009 Sales 2Corgenix Reports Second Quarter Fiscal 2010 Financial Results 2Corgenix Reports Second Quarter Fiscal 2010 Financial Results 3Corgenix Reports Second Quarter Fiscal 2010 Financial Results 4
(Date:9/22/2014)... The Gesundheit! Institute founded by Patch ... restructuring for their existing website. The Institute had outgrown their ... way to navigate to the different branches of the organization ... look and feel of the site in a more fun ... Adams graduated from The Medical School of Virginia, he began ...
(Date:9/22/2014)... September 23, 2014 Career Step, ... training, will be attending and exhibiting at the ... Health Information Management Association (AHIMA) in San Diego, ... through October 1, and Career Step will be ... suite of coding training products, including CLiMâ„¢, its ...
(Date:9/22/2014)... Portland, Oregon (PRWEB) September 22, 2014 ... Convention, key leaders from the Oregon long-term care and ... go the extra mile for the well-being of others. ... Operations for Avamere Health Services, will be awarded the ... year by OHCA staff to members who assist OHCA ...
(Date:9/22/2014)... On Saturday, September 27, UHY LLP and UHY ... that is doing an amazing job helping kids and refurbishing ... families and friends will be spending the day at Academy ... and graphics, as well as clean the playground and surrounding ... occur in May but due to weather conditions it was ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Locating the ... industry is now easier using the Quotes Pros portal ... trying to local universal life insurance pricing from different ... coverage plans that are easily viewed when using the ... specific lengths of coverage. The plan data can be ...
Breaking Medicine News(10 mins):Health News:Idea Marketing Group Launches a New Website for The Gesundheit! Institute 2Health News:Idea Marketing Group Launches a New Website for The Gesundheit! Institute 3Health News:Career Step to Exhibit at AHIMA Convention September 27 through October 1 2Health News:Avamere Family of Companies Regional Director Nominated for the Oregon Health Care Association 2014 Special Service Award 2Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 2Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 3Health News:Universal Life Insurance Prices for Adults Added to National Insurer Portal Online 2
... ... ... , ... , , , ...
... ... ... ... ...
... Tiny bits of molecular "trash" found in circulating blood ... untimely death, say researchers at Duke University Medical Center. ... issue of the journal Circulation Genetics , comes ... disease, and is the first to identify specific metabolic ...
... tests with rats, tea consumption reduced oxidative stress, researchers say ... green tea work their way into the tissues of the ... researchers say. , The findings, published in the current ... , suggest that the substances, known as catechins, are absorbed ...
... could work, but application remains years away , FRIDAY, Feb. ... first to hint that gene therapy could become a weapon ... remains far from being ready for use by patients, and ... is "a step in the direction of using gene therapy" ...
... ... , ... ... TROY, Mich. , Feb. 19 Joseph F. Page will be a guest speaker at the University of Michigan on ...
Cached Medicine News:Health News:RetireSafe Survey Says Seniors Are Struggling With Increased Costs Without an Increased Social Security Cost of Living Adjustment 2Health News:RetireSafe Survey Says Seniors Are Struggling With Increased Costs Without an Increased Social Security Cost of Living Adjustment 3Health News:Cunard's Queen Victoria is 'Pretty in Pink' in Sydney 2Health News:Tiny molecules may tell big story about cardiovascular disease risk 2Health News:Tiny molecules may tell big story about cardiovascular disease risk 3Health News:Gene Therapy Shows Promise Against HIV 2Health News:Giarmarco, Mullins & Horton, P.C. President Joseph F. Page to Speak at University of Michigan 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: